Chen, Xiao-Jun
Jiang, Kai
Ferguson, Christopher M.
Tang, Hui
Zhu, Xiangyang
Lerman, Amir
Lerman, Lilach O. http://orcid.org/0000-0002-3271-3887
Article History
Received: 28 January 2020
Revised: 3 August 2020
Accepted: 20 August 2020
First Online: 14 September 2020
Competing interests
: L.O.L. receives funding from Novo Nordisk and advises Weijian Technologies and AstraZeneca.